Maine LD480 would provide MaineCare coverage for certain FDA-approved weight loss medications.
Maine LD480 would require the Department of Health and Human Services to provide reimbursement under the MaineCare program for glucagon-like peptide-1 receptor agonists that are approved by the federal Food and Drug Administration for the treatment of obesity. The bill specifies that reimbursement is restricted to medications prescribed by a primary care provider or a bariatric specialist and mandates a prior authorization for these medications.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.